Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$570K-70.2%
LBR
LB Pharmaceuticals IncLBRX
-$17K-242%
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc.MPLT
$814K+217%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$50K-96.7%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$955.82M-16.0%
Enterprise value$810.41M-19.5%
P/E20×-11.4×
P/S1.2×-0.4×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Non-cash lease benefit(175)(60)
Non-cash interest expense for amortization of debt discount and issuance costs1,9012,722
Net (amortization) accretion for deferred royalty obligation(206)2,014
Net amortization of premiums and discounts on investments(223)(588)
Change in fair value of contingent consideration(1,144)
Changes in operating assets and liabilities:
Accounts receivable(15,305)15,509
Inventory(2,426)(2,588)

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s accretion (amortization) of discounts and premiums, investments?
Collegium Pharmaceutical, Inc. (COLL) reported accretion (amortization) of discounts and premiums, investments of $45K in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Collegium Pharmaceutical, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 83.0% year-over-year, from $264K to $45K.
What does accretion (amortization) of discounts and premiums, investments mean?
The periodic adjustment to the carrying value of investment securities to reflect the amortization of premiums or accretion of discounts. This non-cash adjustment aligns the investment's book value with its expected redemption value over time.

Ask your AI about Collegium Pharmaceutical, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude